

Leishmaniasis

PERU

2014

Published in July 2016

Country General Information (WHO, 2013)

Total population:	30,376,000	Age group <15/>14 years, %:	29% / 71%
Gender (% F/M):	49.9% / 50.1%	Life expectancy at birth in years (F/M):	77/72
GDP (PPP int \$):	11 360	Number of 2nd sub-national administrative level divisions, name:	196, Province
Income status:	Upper middle		

Epidemiology


	VL	CL ^d	PKDL	MCL ^d
Endemicity status:	Non endemic	Endemic	Non-endemic	Endemic
Number of new cases (incidence):	N/A	5888	N/A	343
Number of relapse cases:	N/A	No data	N/A	No data
Total number of cases:	N/A	5888	N/A	343
Imported cases (n, %):	0	No data	No data	No data
Gender distribution (% F):	N/A	35%	N/A	No data
Age group distribution (% <5-5-19/>19): ^a	N/A	(10/34/56)	N/A	No data
Incidence rate (cases/10 000 population in endemic areas): ^{b,c}	0	2.70	N/A	No data
Number of endemic 2nd sub-national administrative level divisions (n) ^c :	0	124	N/A	No data
Population at risk ^{1,c} (% n/total):	0%	74% (23039846 / 30973148)	N/A	No data
Was there any outbreak?	No	No data	N/A	No data
Number of new ² foci:	0	No data	N/A	No data

N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis


Monthly distribution of new cases January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	0	0	0	0	0	0	0	0	0	0	0
CL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data

Number of new CL cases reported by month* in 2013 and 2014



Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014



¹ Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

* No data available

² For this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever

³ Incidence rate at the national level

^a In the Region of the Americas, the age groups used for reporting are <5 years, 5-9y, 10-19y, 20-49y and 50y and older


^b In the Region of the Americas, leishmaniasis incidence rate is usually calculated /100 000 population; to be comparable with other countries, it is reported here as /10 000 population

^c In the Region of the Americas, the endemic areas used for the calculation of incidence rate and population-at-risk were the lowest sub-national administrative levels reporting cases in 2014.

^d In the Region of the Americas, except for the number of cases, all the indicators include both CL and MCL cases

Distribution of new CL (left) and new (primary) VL (right) cases

Incidence of CL in Peru in 2014 at province level per 10 000 population



Not endemic for VL

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available	Year latest national guidelines were published:	1993
Type of surveillance:	Other	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	No
Type of insecticide used for IRS:	Pyrethroid	Number of leishmaniasis health facilities:	1784

Diagnosis

	VL	CL	PKDL	MCL
Number of people clinically screened actively for:	N/A	No data	N/A	No data
Number of people clinically screened passively for:	N/A	No data	N/A	No data
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):	N/A	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	N/A	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides +/total cases):	N/A	100% (6221/6231)	N/A	N/A
Proportion of positive slides (%, # slides +/total slides):	N/A	No data	N/A	N/A
Cases diagnosed clinically (%, # clinical cases/total cases):	N/A	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	N/A	N/A	N/A	N/A

* These indicators apply only for new (primary) VL cases.

VL = visceral leishmaniasis

CL = cutaneous leishmaniasis

PKDL = post-kala-azar dermal leishmaniasis

N/A = not applicable

RDT = rapid diagnostic test

HIV = human immunodeficiency virus

MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Amphotericin B deoxycholate, Meglumine antimoniate, Miltefosine*, Sodium stibogluconate (SSG), Pentamidine*

*included but not available

TREATMENT OUTCOME

	VL
Proportion of relapse cases: ⁴	N/A
Initial cure rate:	N/A
Failure ⁵ rate:	N/A
Case-fatality rate: ⁶	N/A

⁴ A relapse case in this country is defined as: A case that returns with signs and symptoms after being initially cured

⁵ A failure case in this country is defined as: A case that does not improve, or gets worse during the treatment period

⁶ Case-fatality rate includes deaths that occurred during treatment as well as deaths from other causes

Data source: Ministry of Health, Peru
© WHO 2014. All rights reserved.